Oral News and Research

RSS

FDA approves NDA filing for ibrutinib inhibitor in two B-cell malignancies

Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

29 Aug 2013

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

Experts share tips on preventing ovarian cancer

Ovarian cancer is the fourth leading cause of death in American women. Approximately 22,000 women are diagnosed annually and 14,000 die from the disease. September is Ovarian Cancer Awareness month and Mount Sinai experts are sharing tips on prevention.

29 Aug 2013

Oral sunscreens not as effective as traditional lotions and creams, warns Loyola dermatologist

While it might be nice to pop a pill to protect your skin from the sun, a Loyola University Health System dermatologist warns that oral sunscreens are not as effective as traditional lotions and creams.

29 Aug 2013

New clinical recommendations urge women to maintain periodontal health during pregnancy

When a woman becomes pregnant, she knows it is important to maintain a healthy lifestyle to ensure both the health of herself and the health of her baby. New clinical recommendations from the American Academy of Periodontology and the Eurpean Federation of Periodontology urge pregnant women to maintain periodontal health as well.

29 Aug 2013

New polymer additives enhance ability of oral drugs to reach bloodstream

All too often, when a person takes a pill full of a potent and effective drug, the drug passes straight through the body, not reaching the organ where it is needed — a waste of money and inconvenient if it is a cold medicine, but potentially dire if it is a treatment for a serious illness.

28 Aug 2013

Personalised management: The only way to close mortality gap for AF patients

Personalised management is the only way to close the mortality gap for patients with atrial fibrillation, according to an ESC consensus paper presented at ESC Congress 2013 by Professor Paulus Kirchhof (UK).

27 Aug 2013

University of Utah started construction on Ray and Tye Noorda Oral Health Education Building

The University of Utah on Friday, Aug. 23, 2013, broke ground on the $36.4 million Ray and Tye Noorda Oral Health Education Building, which when completed in December 2014 will house the University's new School of Dentistry.

27 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

Powerful new option for treating vasculitis

In a study published in the New England Journal of Medicine, a research consortium that includes the University of Alabama at Birmingham (UAB) has shown that a new drug for vasculitis, a potentially life-threatening auto-immune disease which causes inflammation in blood vessels, is as effective as standard therapy over 18 months.

27 Aug 2013

Review Article examines FMT methodology as effective treatment for C. difficile infection

Fecal microbiota transplantation has emerged as a highly effective treatment for recurrent Clostridium difficile infection, with very early experience suggesting that it may also play a role in treating other gastrointestinal and non-GI diseases.

23 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

MicuRx Pharmaceuticals raises $25 million in Series B financing

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures.

22 Aug 2013

In dynamic mind-body interaction, brain recruits cells from immune system to promote anxiety

New research shows that in a dynamic mind-body interaction during the interpretation of prolonged stress, cells from the immune system are recruited to the brain and promote symptoms of anxiety.

22 Aug 2013

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

22 Aug 2013

DFID awards 5-year grant to DNDi to advance research and development for neglected diseases

The UK Department for International Development (DFID) has announced its renewed support to the Drugs for Neglected Diseases initiative (DNDi), allocating a total of - 30 million (- 35 million) over the coming five years (2013-2018) to DNDi's Research & Development (R&D) portfolio to fight neglected diseases.

22 Aug 2013

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule, ORMD-0801 for patients with type 1 diabetes mellitus in Israel.

22 Aug 2013

Alarm therapy or drug therapy may solve bedwetting problems in children

Bedwetting affects up to 20 percent of five year olds—the age when most children have learned bladder control—and can result in an array of stressful and embarrassing social, emotional and psychological problems.

21 Aug 2013

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

Vertex Pharmaceuticals (Australia) Pty Ltd., announces the presentation of data from KALYDECO (ivacaftor) studies at the 10th Australasian Cystic Fibrosis Conference in Auckland, New Zealand, August 17 – 20, 2013, which further demonstrate the benefits of the medicine in people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

21 Aug 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

Oral News and Research

FDA approves NDA filing for ibrutinib inhibitor in two B-cell malignancies

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

Experts share tips on preventing ovarian cancer

Oral sunscreens not as effective as traditional lotions and creams, warns Loyola dermatologist

New clinical recommendations urge women to maintain periodontal health during pregnancy

New polymer additives enhance ability of oral drugs to reach bloodstream

Personalised management: The only way to close mortality gap for AF patients

University of Utah started construction on Ray and Tye Noorda Oral Health Education Building

FDA grants Priority Review designation to sNDA for Nexavar tablets

Powerful new option for treating vasculitis

Review Article examines FMT methodology as effective treatment for C. difficile infection

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

MicuRx Pharmaceuticals raises $25 million in Series B financing

In dynamic mind-body interaction, brain recruits cells from immune system to promote anxiety

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

DFID awards 5-year grant to DNDi to advance research and development for neglected diseases

Oramed starts patient recruitment in Israel for ORMD-0801 clinical trial for patients with T1DM

Alarm therapy or drug therapy may solve bedwetting problems in children

Twice-daily KALYDECO improves lung function in people with cystic fibrosis

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News